Chronic Myelogenous Leukemia Treatment Market Size
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.30 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Chronic Myelogenous Leukemia Treatment Market Analysis
The chronic myelogenous leukemia (CML) treatment market is expected to register a CAGR of 5.3% over the forecast period.
The initial impact of the pandemic on the studied market was considered adverse, owing to the decrease in procedures during that phase. CML patients possess a weakened immune system; thus, they were at risk of COVID-19 infection during the initial phase of the pandemic. As a result, various studies were conducted to determine the impact of COVID-19 on CML patients. According to research data published in the Cureus Journal of Medical Science (Cureus) in April 2022, immunocompromised patients, including those with hematologic malignancies such as patients with CML who needed hospitalization and COVID-19 infection, were linked to worse outcomes. Such instances created a demand for CML drugs and therapies during the pandemic. In addition, in the current times where everything is normalized despite COVID-19, the treatments for CML patients are smoothly ongoing, and development activities by major players are also proceeding at a steady pace.
The burden of chronic myelogenous leukemia (CML) among the global population is expected to be the major driving factor for the chronic myelogenous leukemia treatment market as awareness about the disease is increasing among people. For instance, as per the June 2022 research study by the American Journal of Hematology, the global incidence of CML is about 1-2 cases per 100,000 population. Further, as per the ACS 2022 report, approximately 15% of all leukemia cases are CML and it primarily affects adults, and the average diagnosis age of CML is about 64 years with the majority of cases being diagnosed in people of age 65 years and older. It can be said that the geriatric population is more susceptible to this disease and their growing population is further expected to have a significant impact on the market.
Furthermore, the regional and global market players focus more on research and development (R&D) in CML treatment. This focus on R&D is mainly centered on product development, innovation, and launches, which are expected to increase product availability and competition in the market, which is predicted to boost the market growth. For instance, in August 2022, Scemblix developed by Novartis AG was approved by the European Commission for adult patients with CML, offering a new treatment approach for patients with intolerance to other therapies.
Factors such as growing awareness among the target population about CML and increasing product development by market payers will pave the way for the studied market to witness growth over the forecast period. However, the side effects associated with chemotherapy and the stringent drug regulations can stand in the way of this growth.
Chronic Myelogenous Leukemia Treatment Market Trends
This section covers the major market trends shaping the Chronic Myelogenous Leukemia Treatment Market according to our research experts:
The Chemotherapy Segment is Expected to Witness Significant Growth Over the Forecast Period
Chemotherapy or chemo is a type of cancer treatment where one or more anti-cancer medications are used as part of a regular chemotherapy program. In simple terms, the application of anti-cancer medications is known as chemotherapy. The anti-cancer drugs are generally injected into a vein or taken by mouth. These drugs enter the bloodstream and reach all areas of the body and are useful for cancers like chronic myeloid leukemia (CML). With the increasing prevalence of CML among the target population globally, the demand for chemotherapy is increasing.
According to Piedmont Healthcare, chemotherapy has improved in recent years and in 2022, has been one of the most preferred cancer therapies. Additionally, as per the source above, chemotherapy is one of the best options for cancer treatment because it attacks cancer cells that are visible but can't be removed through surgery or radiation.
Furthermore, chemotherapy is generally used in patients with blast phase disease to get the CML back into the chronic phase. In some cases, the procedure used to get patients ready for an allogeneic stem cell transplant will include very high doses of chemotherapy. There are several medications on the market that can be used as chemotherapy drugs to treat CML. For instance, according to the LLS 2022 update, Omacetaxine mepesuccinate (Synribo) is one of the major products that is approved by the FDA for CML treatment. Thus, the availability of drugs for chemotherapy of CML treatment is anticipated to fuel the segment growth.
Moreover, there are increased research activities to develop more advanced chemotherapy which can offer benefits over conventional chemotherapy. For instance, as per a study published in PMC in July 2022, when patients with haematologic malignancies including CML received chemotherapy and adjuvant sodium selenite (0.2 mg/kg/day) for 7 days, they presented increased apoptosis in lymphoma cells, as measured by flow cytometry, relative to the patients who received only conventional chemotherapy. Thus, these advancements in chemotherapy are anticipated to drive segment growth.
North America is Anticipated to Witness Significant Growth Over the Forecast Period
North America is anticipated to witness growth over the forecast period and dominate the market. Increasing healthcare expenditure, a rising prevalence of CML, and the rising geriatric population across the region are the primary drivers for the CML treatment market in the region.
Among other countries in the region, the United States is expected to hold the highest market share during the forecast period. CML affects the bone marrow and blood; during that time, the bone marrow overproduces granulocytes, a type of white blood cell. According to research and various sources, CML is a rare form of adult leukemia, which is higher in older adults because their ability to fight infection reduces with age. The data updated by the ACS in January 2022 indicated that nearly 8,860 new cases of CML were expected to be diagnosed in 2022 in the United States.
In addition, the source mentioned above stated that nearly 15% of all new cases of leukemia are CML, where approximately 1 in 526 persons is estimated to get CML in their lifetime in the United States. Data updated in February 2022 by HHS shows that the population in the United States is aging unprecedently and the population aged 65 or older in the country is projected to reach 23.5% (98 million) by 2060. With the increasing geriatric population in the country, the risk of CML is also rising. This is expected to generate demand for drugs and therapy for the treatment of the disease.
Moreover, the increasing development of various treatment options in the country is anticipated to drive market growth over the forecast period. For instance, in October 2021, Scemblix (asciminib) developed by Novartis AG for the treatment of chronic myeloid leukemia (CML) in two distinct indications received FDA approval. Scemblix is the first FDA-approved CML treatment that works by binding to the ABL myristoyl pocket and represents an important development for patients who experience resistance and/or intolerance to currently available tyrosine kinase inhibitor (TKI) therapies. Such developments in the country are increasing the focus of the market players toward innovations. This is expected to cater to the market growth, further impacting the overall market growth in the region.
Chronic Myelogenous Leukemia Treatment Industry Overview
The chronic myelogenous leukemia treatment market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Bristol-Myers Squibb Co., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Mylan NV, Merck & Co. Inc, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, and Sanofi, among others.
Chronic Myelogenous Leukemia Treatment Market Leaders
-
Bristol-Myers Squibb Co
-
Pfizer, Inc.
-
Teva Pharmaceutical Industries Ltd.
-
Takeda Pharmaceutical Co. Ltd
-
Novartis AG
*Disclaimer: Major Players sorted in no particular order
Chronic Myelogenous Leukemia Treatment Market News
- In July 2022, the Center for Drug Evaluation (CDE) of China of the National Medical Products Administration (NMPA) accepted and granted Priority Review designation to a New Drug Application (NDA) submitted by Innovent Biologics, Inc. and Ascentage Pharma that will support the full approval of olverembatinib in patients with chronic-phase chronic myeloid leukemia (CML-CP) who are resistant and/or intolerant of first- and second-generation tyrosine kinase inhibitors (TKIs).
- In December 2021, Ascentage Pharma launched its innovative drug Olverembatinib in China to treat adult patients in the chronic or accelerated phase of chronic myeloid leukemia (CML). Olverembatinib is the first of its kind in China and is manufactured by Guangzhou HealthQuest Pharma Co Ltd Inc, a wholly-owned subsidiary of Ascentage Pharma.
Chronic Myelogenous Leukemia Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Incidence and Prevalence of Chronic Myeloid Leukemia
4.2.2 Advancement in Drug Development
4.2.3 Increasing Investments in Research and Development
4.3 Market Restraints
4.3.1 Side effects Associated with Chemotherapy
4.3.2 Stringent Regulations on Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Treatment Type
5.1.1 Targeted therapy
5.1.2 Chemotherapy
5.1.3 Biologic therapy
5.1.4 Other Treatment Types
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East and Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East and Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bristol-Myers Squibb Co.
6.1.2 Novartis AG
6.1.3 Pfizer Inc.
6.1.4 Takeda Pharmaceutical Company Limited
6.1.5 Teva Pharmaceutical Industries Ltd.
6.1.6 Viatris Inc. (Mylan)
6.1.7 Merck & Co., Inc.
6.1.8 F. Hoffmann-La Roche Ltd.
6.1.9 Boehringer Ingelheim International GmbH
6.1.10 Sanofi
6.1.11 Cipla Inc. (Cipla USA Inc.)
6.1.12 Amneal Pharmaceuticals LLC
6.1.13 Accord Healthcare, Inc
6.1.14 Fresenius Kabi AG
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Chronic Myelogenous Leukemia Treatment Industry Segmentation
Chronic myelogenous leukemia, also known as chronic myeloid leukemia (CML) is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. The Chronic Myelogenous Leukemia Treatment Market is segmented by Treatment Type (Targeted therapy, Chemotherapy, Biologic Therapy, and Others) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Treatment Type | |
| Targeted therapy | |
| Chemotherapy | |
| Biologic therapy | |
| Other Treatment Types |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Chronic Myelogenous Leukemia Treatment Market Research FAQs
What is the current Chronic Myelogenous Leukemia Treatment Market size?
The Chronic Myelogenous Leukemia Treatment Market is projected to register a CAGR of 5.30% during the forecast period (2024-2029)
Who are the key players in Chronic Myelogenous Leukemia Treatment Market?
Bristol-Myers Squibb Co, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd and Novartis AG are the major companies operating in the Chronic Myelogenous Leukemia Treatment Market.
Which is the fastest growing region in Chronic Myelogenous Leukemia Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Chronic Myelogenous Leukemia Treatment Market?
In 2024, the North America accounts for the largest market share in Chronic Myelogenous Leukemia Treatment Market.
What years does this Chronic Myelogenous Leukemia Treatment Market cover?
The report covers the Chronic Myelogenous Leukemia Treatment Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Chronic Myelogenous Leukemia Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Chronic Myelogenous Leukemia Treatment Industry Report
Statistics for the 2024 Chronic Myelogenous Leukemia Treatment market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Chronic Myelogenous Leukemia Treatment analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Chronic Myelogenous Leukemia Treatment Market Report Snapshots
